Biomarkers of Disease Outcomes and Resistance Mechanisms to First-Line Osimertinib in Patients With Advanced EGFR-Mutant Lung Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers
Eur J Surg Oncol 2022 Dec 06;[EPub Ahead of Print], NJ Choudhury, A Marra, JSY Sui, J Flynn, SR Yang, CJ Falcon, P Selenica, AJ Schoenfeld, N Rekhtman, D Gomez, MF Berger, M Ladanyi, M Arcila, CM Rudin, GJ Riely, MG Kris, G Heller, JS Reis-Filho, HA YuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.